February 13, 2025 - Qingdao Baheal Pharma Co., Ltd. (hereinafter referred to as "Baheal Medical," 301015.SZ), a leading pharmaceutical industrialization platform, has announced a new commercial collaboration with Shanghai Roche Pharmaceuticals Ltd. ("Roche Pharmaceuticals China").

Under the terms of the agreement, Baheal Medical will hold the exclusive rights to market Roche's classic oncology targeted drug, MabThera® (generic name: Rituximab), in mainland China.This renewed partnership aims to enhance the accessibility of this iconic oncology medication in China, offering more high-quality treatment options to patients.

As the world's first monoclonal antibody specifically targeting the CD20 antigen, MabThera® is also the world's first monoclonal antibody for anti-tumor treatment, opening a new era of tumor targeted therapy. MabThera® has accumulated more than 20 years of clinical experience worldwide and has benefited more than 6.8 million patients. The drug is mainly used for the treatment of diseases such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Based on a large amount of clinical research data and long-term real-world data, MabThera® has been proven to have good safety, and its combined chemotherapy regimen can significantly improve the clinical cure rate of patients, delay disease progression and prolong survival time. In China, MabThera® was approved for listing in April 2000, was included in the "National Medical Insurance Drug List" in July 2017, and two new indications were approved in 2019, further expanding its market space.

Baheal Medical, as a leading force in pharmaceutical industrialization, focuses on optimizing healthcare scenarios through technological innovation and ensuring widespread use of products with significant clinical value. Previously, Baheal collaborated with Roche in the oncology sector. This renewed partnership aims to leverage Baheal's comprehensive brands operation capabilities to enhance the accessibility of MabThera®, enriching its brand value and extending its reach to more patients in need.

Baheal Pharma's current product matrix spans four major categories: OTC and Healthcare products, OTX prescription medicines, oncology and critical diseases medications and high-end medical devices. With the addition of MabThera®, Baheal's oncology line is strengthened, fostering synergy among multiple oncology products and potentially driving performance growth.

Looking forward, Baheal Medical remains committed to addressing clinical needs by continually optimizing and expanding its product offerings. The company is devoted to delivering superior pharmaceutical and healthcare products & solutions to a broad patient base, striving to enhance public health and welfare on a larger scale.